Capital Performance Advisors »

Lineage Cell Therapeutics In shares owned by Capital Performance Advisors

Quarter-by-quarter ownership of Lineage Cell Therapeutics In (LCTX) shares owned by Capital Performance Advisors from 13F filings

Historical chart of Capital Performance Advisors investment in Lineage Cell Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including Lineage Cell Therapeutics In held by Capital Performance Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lineage Cell Therapeutics In by Capital Performance Advisors

Quarter filed Position value Share count Share price at filing
2024-09-30 $148 163 0.91

More positions owned by Capital Performance Advisors

Dimensional Etf Trust Us Core Equity 2 (DFAC)
Dimensional Etf Trust Us Targeted Vlu (DFAT)
Dimensional Etf Trust Us Mktwide Value (DFUV)
Dimensional Etf Trust Internatnal Val (DFIV)
Apple (AAPL)
Ishares Tr Core S&p500 Etf (IVV)
Dimensional Etf Trust Us Equity Market (DFUS)
Dimensional Etf Trust Us Small Cap Etf (DFAS)
Microsoft Corporation (MSFT)
American Centy Etf Tr Us Sml Cp Valu (AVUV)
Vanguard Index Fds Total Stk Mkt (VTI)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
Amazon (AMZN)
Vanguard Specialized Funds Div App Etf (VIG)
NVIDIA Corporation (NVDA)

View all positions for Capital Performance Advisors

Top funds holding Lineage Cell Therapeutics In

Broadwood Capital
BlackRock
Vanguard Group
Perceptive Advisors
Defender Capital
Raffles Associates
Alyeska Investment Group
Geode Capital Management
State Street Corporation
DAFNA Capital Management
Renaissance Technologies
Northern Trust
Jacobs Levy Equity Management
Jpmorgan Chase & Co
Brian McDonald

View all funds holding Lineage Cell Therapeutics In